Veracyte, Inc. (VCYT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Veracyte, Inc. (VCYT) is up 26.3% since the beginning of the year. At $53 per share, VCYT is trading just below its 52-week high of $55. Investors who bought $1,000 worth of VCYT shares 5 years ago would now be looking at an investment worth $1,361.

Veracyte, Inc. (VCYT) has returned 26.34% so far this year and 101.55% over the past 12 months. Looking at the last ten years, VCYT has achieved an annualized return of 26.55%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.

Based on dividend-adjusted daily data since Oct 30, 2013, VCYT's average daily return is +0.12%, while the average monthly return is +2.33%. At this rate, an investment would double in approximately 2.5 years.

Historically, 50% of months were positive and 50% were negative. The best month was Nov 2020 with a return of +57.3%, while the worst month was Sep 2015 at -50.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.

On a daily basis, VCYT closed higher 49% of trading days. The best single day was Oct 31, 2018 with a return of +28.5%, while the worst single day was Sep 28, 2015 at -21.6%.

Veracyte, Inc. has an annualized alpha of 9.84%, beta of 1.57, and R2 of 0.20 versus S&P 500 Index. Calculated based on daily prices since October 30, 2013.

• This stock participated in 142.76% of S&P 500 Index downside but only 142.43% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.20 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

VCYT ranks 83 for risk / return — in the top 83% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Veracyte, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Veracyte, Inc. was 81.19%, occurring on Oct 20, 2022. The portfolio has not yet recovered.

The current Veracyte, Inc. drawdown is 34.64%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Veracyte, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Veracyte, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.